SCHEMBL24700600

SCHEMBL24700600

COc1cccc2c1C(C(=O)NCCc1ccccc1)C(C)(C)CC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.50
ATM Q13315 1/20 0.44
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
POLB P06746 2/20 0.43
TP53 P04637 1/20 0.43
KCNA3 P22001 1/20 0.42
KDM4E B2RXH2 1/20 0.42
HTR1A P08908 3/20 0.41
DRD2 P14416 1/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP1A2 P05177 1/20 0.41
GAA P10253 1/20 0.41
ALOX12 P18054 1/20 0.41
CYP2C19 P33261 1/20 0.41
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23123410 0.73 TAAR1 (0.50) TAAR1ATMNPC1RAB9APOLB
SCHEMBL8969478 0.72 TAAR1 (0.51) TAAR1ATMNPC1RAB9ATP53
SCHEMBL22365514 0.71 TAAR1 (0.55) TAAR1NPC1RAB9APOLBTP53
SCHEMBL22365527 0.71 TAAR1 (0.50) TAAR1NPC1RAB9APOLBCYP3A4
SCHEMBL22365521 0.68 TAAR1 (0.58) TAAR1NPC1RAB9APOLBTP53
SCHEMBL7279469 0.65 ALDH1A1 (0.71) NPC1RAB9APOLBTP53KDM4E
SCHEMBL24700489 0.65 CYP2C19 (0.48) TAAR1POLBCYP3A4CYP2D6GAA
SCHEMBL7279475 0.65 ALDH1A1 (0.71) NPC1RAB9APOLBTP53KDM4E
SCHEMBL5156747 0.65 TAAR1 (0.74) TAAR1NPC1RAB9ATP53ALDH1A1
SCHEMBL5789543 0.65 KDM4E (0.52) TAAR1POLBKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220380314-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380314-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GBA2, CLN6 TAAR1 2029/4885ATM 4171/4885NPC1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.